-
Mashup Score: 12ACC 2021 Prevention Highlights – ADAPTABLE and STRENGTH Trials - 3 year(s) ago
ACC 2021 Prevention Highlights where CardioNerds discuss ADAPTABLE and STRENGTH Trials with Dr. Gina Lundberg and Dr. Steven Nissen
Source: CardionerdsCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 0The Clinical Impact of the ADAPTABLE Trial - 3 year(s) ago
W. Schuyler Jones, MD, and Manesh Patel, MD discuss the influences the aspirin-dosing cardiology trial may have on future studies.
Source: HCPLiveCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 1The Clinical Impact of the ADAPTABLE Trial - 3 year(s) ago
W. Schuyler Jones, MD, and Manesh Patel, MD discuss the influences the aspirin-dosing cardiology trial may have on future studies.
Source: HCPLiveCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0The Clinical Impact of the ADAPTABLE Trial - 3 year(s) ago
W. Schuyler Jones, MD, and Manesh Patel, MD discuss the influences the aspirin-dosing cardiology trial may have on future studies.
Source: HCPLiveCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 2ADAPTABLE: Similar Benefit, Bleeding Risk With Low- and High-Dose Aspirin For Secondary Prevention - American College of Cardiology - 3 year(s) ago
In a trial designed to try to answer the longstanding question of the optimal dose of aspirin for secondary prevention in patients with established atherosclerotic cardiovascular disease, no significant difference was found in cardiovascular events or major bleeding between the 81 mg and 325 mg daily doses, according to results of the ADAPTABLE study presented May 15 during ACC.21 and…
Source: American College of CardiologyCategories: Cardiology News and Journals, Latest HeadlinesTweet-
ICYMI: In a trial designed to try to answer Q of optimal dose of #aspirin for secondary prev in patients w/ established atherosclerotic #CVD, no signif. diff. found in CV events/major bleeding btwn the 81 mg & 325 mg daily doses. https://t.co/ejnAAh5eLs #ADAPTABLE #ACC21 @NEJM https://t.co/oiRoxpzBhM
-
-
Mashup Score: 0ADAPTABLE, with Schuyler Jones, MD, and Manesh Patel, MD - 3 year(s) ago
The first episode of the Heart Trials podcast series focuses on new ACC 2021 research into aspirin dosages for reduced cardiovascular event risk.
Source: HCPLiveCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0ADAPTABLE: Low-dose aspirin as good as high-dose in CHD? - 3 year(s) ago
A large randomized trial specifically designed to investigate the optimum dose of aspirin in patients with established coronary disease has found similar efficacy and safety with 81 mg and 325 mg.
Source: www.mdedge.comCategories: Cardiology News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1
Dr. Kim Eagle, Dr. Deepak Bhatt, and Dr. Payal Kohli look back on Day 1 of ACC.201 late-breaking science and featured clinical research, including LAAOS III (0:38), ATLANTIS (4:07), ADAPTABLE (8:02), EXPLORER-HCM (13:25), and PARADISE-MI (16:59). Clinical Topics: Acute Coronary Syndromes, Anticoagulation Management, Arrhythmias and Clinical EP, Atherosclerotic Disease (CAD/PAD),…
Source: American College of CardiologyCategories: Cardiology News and Journals, Latest HeadlinesTweet
-
Mashup Score: 3
Dr. Kim Eagle, Dr. Deepak Bhatt, and Dr. Payal Kohli look back on Day 1 of ACC.201 late-breaking science and featured clinical research, including LAAOS III (0:38), ATLANTIS (4:07), ADAPTABLE (8:02), EXPLORER-HCM (13:25), and PARADISE-MI (16:59). Clinical Topics: Acute Coronary Syndromes, Anticoagulation Management, Arrhythmias and Clinical EP, Atherosclerotic Disease (CAD/PAD),…
Source: American College of CardiologyCategories: Cardiology News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0ADAPTABLE, with Schuyler Jones, MD, and Manesh Patel, MD - 3 year(s) ago
The first episode of the Heart Trials podcast series focuses on new ACC 2021 research into aspirin dosages for reduced cardiovascular event risk.
Source: HCPLiveCategories: General Medicine News, Latest HeadlinesTweet
🎤#ACC2021 Prevention Highlights – #ADAPTABLE & #STRENGTH Trials with Drs. @gina_lundberg & Steven Nissen 🙏A collab with ACC Prevention of CV Disease Council @DrEugeneYang @AnumSaeedMD @mahrifai @CardioNerds @AmitGoyalMD @RichardAFerraro @ThomasMDas 🔗https://t.co/sIzwHTGfgn https://t.co/5FwtUdNnHz